RETRACTED

Development of a lyophilized preparation enriched with hepatocyte growth factor

P.O. Inozemcev[1*], *G.E.* Grigoriev[1], and *S.A.* Lepekhova[1]

[1]Irkutsk scientific center the Siberian Branch of the Russian Academy of Sciences, 134 Lermontov St., Irkutsk, 664033, Russia

Abstract. The study was performed using neonatal livers from Wistar rats. To obtain cells, it is proposed to use a mixed disaggregation method. A significant increase in the amount of the regulatory peptide on the 5th day was revealed to 46.8 (38.4–50.0) ng/ml, and therefore for lyophilization it is better to use a 5-day cell culture containing the maximum amount of HGF. Optimally selected technological conditions made it possible to preserve biologically active substances secreted by liver cells and obtain a stable form of lyophilized liver cells enriched with hepatocyte growth factor. Key words: lyophilization, liver cells, hepatocyte growth factor, HGF, liver failure.

1 Introduction

In recent years, there has been a trend towards an increase in the number of patients with acute and chronic liver diseases, which can lead to irreversible liver damage and ultimately to the development of liver failure [1]. The main causes leading to acute and chronic liver failure are viral diseases, bacterial infections, and toxic effects [2]. Mortality from acute liver failure has historically exceeded 80%, but survival rates with medical treatment have improved significantly in recent years due to a better understanding of pathophysiology and advances in intensive care management [3].

One of the key points in the treatment of liver failure is pharmacotherapy with the use of hepatoprotectors [4]. However, to date there is no consensus on which drugs can be classified in this group, due to the lack of clear criteria that these drugs must meet. Similar to the dispute over terminology, the effectiveness of certain drugs used as hepatoprotectors is also questioned [5].

To date, liver transplantation is the only clinically effective treatment with a long-term prognosis for end-stage disease [6-8]. Despite the progressive increase in the number of donors and the increase in the number of liver transplantations from deceased donors, the number of patients on the waiting list for transplantation is significantly higher than the number of transplantations [9]. A potential alternative to liver transplantation is allogeneic hepatocyte transplantation.

Cell therapy is playing an increasingly important role in restoring organ function and can be integrated into organ transplantation protocols. Various cell types and sources are

* Corresponding author: p.inozemcev@rambler.ru

© The Authors, published by EDP Sciences. This is an open access article distributed under the terms of the Creative Commons Attribution License 4.0 (https://creativecommons.org/licenses/by/4.0/).

being considered for this purpose, and understanding the underlying mechanisms regulating cell differentiation and proliferation is critical for clinical applications. Since 1992 [10], various approaches have been used to treat liver failure [11], using both individual hepatocytes [12] and a complex of cells [13].

Modern trends in the creation of new medical preparations of natural origin promote the use of tissues and organs of farm animals as raw materials for the development of pharmaceutical substances and biologically active additives. However, there is an urgent issue of technologies for isolating target biologically active substances from raw materials and preserving their activity in the final product and standardization by components.

Hepatocyte growth factor is a multifunctional cytokine that acts on various epithelial cells, regulating cell growth, movement and morphogenesis, as well as tissue regeneration of damaged organs. Hepatocyte growth factor is a heterodimeric molecule consisting of a 69 kDa alpha chain and a 34 kDa beta chain. Mesenchymal cells are responsible for the production of this growth factor: fibroblasts, vascular endothelium (activated as a result of liver damage), smooth muscle cells of the vascular wall, macrophages, activated T-lymphocytes, non-parenchymal liver cells, spleen cells. Hepatocyte growth factor in intact tissue exists as an inactive form. Activation occurs when tissue is damaged due to proteolytic processing, after which regeneration mechanisms are launched through the HGF – c-Met signaling pathway. Many experimental studies have noted the regenerative effect of hepatocyte growth factor, including damage to the gastrointestinal tract and kidneys. Hepatocyte growth factor is directly involved in the restoration of the liver after damage (toxic, infectious, surgical), which makes it a promising therapeutic tool for regenerative medicine.

Neonatal liver is characterized by the fact that it is a natural source of a various complex of biologically active substances, including hepatocyte growth factor (HGF) [14].

It should be noted that human HGF is homologous to feline, mouse, rat (93.2–93.3%) and porcine hepatocyte growth factor [15,16]. Hepatocyte growth factor plays a leading role in the process of liver regeneration, for example, during toxic damage or in the treatment of patients with chronic liver failure, which makes it a promising therapeutic tool for regenerative medicine [17].

The aim of our research was to develop a technology for producing a drug whose effect is based on the action of endogenous liver regeneration factors.

2 Materials and methods

The study protocol was approved by the local ethics committee of the Institute of Scientific Research, Siberian Branch, Russian Academy of Sciences. Experiments on animals were carried out in accordance with the rules of humane treatment of animals, which are regulated by the "Rules for carrying out work using experimental animals", approved by Order of the Ministry of Health of the USSR No. 742 of November 13, 1984 "On approval of the rules for carrying out work using experimental animals" and No. 48 of 01/23/85 "On control over work using experimental animals", and were also based on the provisions of the Helsinki Declaration of the World Medical Association of 1964, amended in 1975, 1983 and 1989. All interventions were performed under aseptic conditions, under general anesthesia. As the object of study in this work, we chose the neonatal liver of Wistar rat pups. To obtain a culture of embryonic liver cells, the technology of mixed disaggregation of embryonic liver tissue was used. Cell counting and viability assessment were performed using a dye exclusion test. A 0.4% aqueous solution of trypan blue (Sigma, USA) was added to the cell suspension, and the number of unstained and stained cells was counted in a Fuchs-Rosenthal chamber. Cultivation was carried out under standard conditions. To assess the amount of HGF, the enzyme-linked immunosorbent assay method was used

RETRACTED

RETRACTED

using the Stat Fax-2000 enzyme-linked immunosorbent analyzer (Awareness technology INC USA). The work used immunoenzyme kits for the specific determination and measurement of HGF (HGF ELISA Kit Biosource, Belgium) in rat blood serum, supernatant, cell culture medium, lyophilisate, and buffer solutions. Lyophilization was carried out at a temperature of -70°C in 50 ml round-bottom flasks, drying time 24 hours, freeze drying BETA 2-8LD plus (Germany) was used. Storage is carried out at a temperature of -70°C. All experimental research data were statistically processed using the Statistica 10.0 program. Differences were considered significant at $p < 0.05$ [18].

3 Results and discussion

Cell isolation technique: liver tissues were obtained under aseptic conditions. Neonatal rat pups were injected intraperitoneally with sodium thiopental solution in the form of a 2.5% solution, and after the onset of anesthesia, a median laparotomy was performed. The extracted organ was placed in a Petri dish and, holding the tissue with tweezers, collagenase was evenly and repeatedly injected throughout the entire volume of the liver tissue using the infiltration method. Using small tweezers and a blade, the liver tissue was crushed with sliding movements, and the vessels and capsule were removed with tweezers. Using tweezers, the suspension was evenly distributed throughout the volume of the medium using zigzag movements. After thermostatting, the fragments were ground again and a suspension was collected from a Petri dish using a syringe. The enzymatically treated tissue macrofragments were then pressed through a series of copper sieves with gradually decreasing mesh sizes (250, 100 μm) and through an intramuscular injection needle. All cellular elements adhering to the sieves and the walls of the needle were washed off with the working medium into a centrifugation tube. The cell suspension along with all washing solutions were combined in a centrifugation tube. After centrifugation, the medium with collagenase was collected from the test tube using a syringe. The supernatant was removed to the level of the precipitated cell suspension. Cell viability was calculated using a dye exclusion test. A 0.4% aqueous solution of trypan blue (Sigma, USA) was added to the cell suspension, and the number of unstained and stained cells was counted in a Fuchs-Rosenthal chamber.

Thus, a suspension of microfragments of 2–5 cells with a high degree of viability was obtained from the embryonic liver. After cell separation on a Ficoll gradient, an average of 8.1 million cells (8.8 (7.4–10.2) × 106; n = 7) were isolated from one gram of liver tissue. 50 ml of suspension contained 41.8 million cells (41.5 (38.5–43.6) × 106; n = 7). The cell viability rate after isolation and purification was 98.9 (98.3–99.4)% (n = 15).

Cultivation technique: the next stage of work was to determine the optimal conditions for culturing embryonic liver cells. During cultivation, we ensured that the cultured cells acquired maximum proliferative activity (Figure 1).



Fig. 1. Daily culture A - macropreparation, 1 - attached liver cells, Romanovsky staining; B - 2-monolayer of embryonic liver cells, hematoxylin-eosin staining 10x40.

When selecting optimal conditions for culturing embryonic liver cells, a relationship was identified between acidification of working solutions and a decrease in the viability of isolated embryonic liver cells.

During the process of cultivation and work with cells, we drew attention to the acidification of the pH of the nutrient media after immersing a suspension of isolated cells in them (pH of standard nutrient media RPMI, 199, Hanks - 7.2), which led to a decrease in the yield of viable cells (Table 1.).

Table 1. Dynamics of changes in liver cell viability in the process of dissociation and pH of working solutions

Cell viability after isolation (%)	n	pH of the environment original	pH of the environment finite	p	r
40–69	8	7.3 (7.1–7.3)	6.8 (6.6–6.9)	$p_U < 0.05$	+ 0.71 $p < 0.05$
70–85	8	7. 4 (7.4–7.4)	7.2 (7.1–7.3)	$p_U < 0.05$	
86–99	8	7.6 (7.6–7.6)	7.4(7.4–7.4)	–	

Note: Significance of differences is determined in comparison with cell viability in the range of 86–99%.

At the next stage of work, we identified the level of change in the pH value of the nutrient medium when placing a suspension of cells in it and assessed their viability after short-term incubation in a nutrient medium with a given pH value, which was determined after the introduction of a suspension of donor material. To do this, cells with the same viability and in the same volume were placed in a culture medium with a variation in the initial pH value of the medium and incubated for a short time (1 hour) at 370 C.

In all observations, there was a decrease in pH. Thus, at initial values in the environment of 7.6–7.8, acidification was 0.2, and at pH values = 7.2–7.4, acidification was more pronounced (0.3). Incubation in a medium with a pH value of 7.6 allowed the cells to be preserved with a maximum degree of viability. Based on the data obtained, it was established that the optimal pH level of the cultivation medium is 7.6.

As a result of changes in cultivation conditions, the processes of proliferative activity of cultured cells slow down, which leads to an extension of the cultivation time. Assessment of the level of hepatocyte growth factor in the liver cell culture medium allowed us to establish that the amount of hepatocyte growth factor changed during the study. The study of the level of hepatocyte growth factor was carried out during cultivation in media with a pH of 7.6.

To assess the functional activity of liver cells in culture, we assessed the level of albumin in the culture medium. This indicator remained unchanged during the observation period: on the first day of cultivation, the albumin level was 8.0 (6.5–9.0) g/l, on the 5th day – 8.7 (6.2–10.0) g /l. At all stages of cultivation, the content of the regulatory peptide HGF in the culture medium was assessed over time, which was used to judge the proliferative activity of the cultured cells.

During the work, a relationship between acidification of working solutions and a decrease in the viability of isolated embryonic liver cells was revealed ($r = +0.71$; $p < 0.05$), and the optimal pH value of working solutions was established to be 7.6.

When cultivation conditions change, the processes of proliferative activity of cultured cells slow down, which requires lengthening the cultivation time. When assessing the level of hepatocyte growth factor in the culture medium of embryonic liver cells, it was revealed that the HGF content changed over the course of the study:

1) medium after centrifugation of isolated hepatocytes (supernatant) – 0.3 (0.17–0.36) ng/ml;

RETRACTED

2) medium after cell centrifugation (supernatant) – 0.66 (0.47–1.02) ng/ml;
3) cultivation medium after 2 days – 14.3 (13–15.6) ng/ml;
4) cultivation medium after 5 days – 46.8 (38.4–50) ng/ml;
5) cultivation medium after 6 days – 31.2 (26.8–34) ng/ml.

From the data presented it follows that on the 5th day of cultivation the HGF content was maximum. A significant increase in the amount of regulatory peptide was detected on day 5 to 46.8 (38.4–50.0) ng/ml versus 14.3 (13–15.6) ng/ml on day 2 (pU = 0.003).

When the highest concentration of the HGF regulatory peptide in the culture medium was reached, the viability of embryonic liver cells was assessed as high and the cell culture was prepared for lyophilization.

Lyophilization technique: cells in the form of a concentrated suspension are placed in sterile 5 ml tubes with a cap. Liver cells are suspended in 9 parts of the drying medium, the concentration of cells in the finished suspension should be 10 vol% (5 ml of a liver cell culture suspension containing 2 x 106 cells in 1 ml, as well as a structure former: 2.5 ml of a 6% solution of polyvinylpyrrolidone, 10 % albumin solution (2 ml) and 10% sucrose solution (0.5 ml)). Lyophilization is carried out at a temperature of -70°C in a 50 ml round-bottom flask, drying time is 24 hours, using freeze drying BETA 2-8LD plus (Germany). Storage is carried out at a temperature of -70°C. The resulting pharmaceutical substance of the liver cell culture lyophilisate has the appearance of a porous mass of yellow-brown color, easily dissolves in physiological solution or in water for injection, forming a straw-yellow liquid with a characteristic odor. A mixture of the following composition was proposed as a structure-forming agent: 6% solution of polyvinylpyrrolidone 2.5 ml and 10% solution of sucrose 0.5 ml. Polyvinylpyrrolidone, being a cryopreservative, prevents damage to liver cells by ice crystals during lyophilization. The use of sucrose in a protective environment allows one to obtain a moderately hypertonic solution, which provides slight dehydration of cells, eliminating the likelihood of osmotic shock and reducing the risk of intracellular crystallization. In this case, polyvinylpyrrolidone acts as a cryopreservative and also has a prolonging effect when using the lyophilisate for injection. The hepatocyte growth factor contained in the lyophilisate is not immediately absorbed from the injection site, but gradually, due to which a prolonged effect is achieved.

4 Conclusion

Based on the purpose of our research to develop a method for obtaining a lyophilized substance enriched with hepatocyte growth factor, we proposed technical methods such as a mixed method of disaggregation, combining mechanical disaggregation, the use of enzymatic digestion of liver tissue to obtain a mixture of parenchymal and non-parenchymal cells in microfragments purified from cellular deuterium in a Ficcoll gradient. For lyophilization, we propose to use a 5-day cell culture containing the maximum amount of hepatocyte growth factor, with optimally selected conditions (cultivation medium, pH of the medium, cultivation time, control of the amount of growth factor in the cultivation medium), and an original drying medium is also proposed for lyophilization, which allows you to preserve biologically active substances and obtain a lyophilized liver cell culture substance enriched with hepatocyte growth factor. Based on these methods, a Russian Federation patent for the invention was obtained [19]. Assessment of specific pharmacological activity is a further stage of the study, with the study of stability depending on storage time, the development of standard quality indicators and the selection of an effective dose.

The proposed biotechnology method is aimed at creating a lyophilized preparation containing hepatocyte growth factor (rat, rabbit, pig cells can be used as a basis), which will presumably be used as a hepatoprotector used for the treatment of liver diseases, by

stimulating the regeneration of liver cells. Created on the basis of a lyophilisate enriched with hepatocyte growth factor, the drug will be in demand for the treatment of patients with liver diseases, which will ultimately help improve the length and quality of life of people on the waiting list for liver transplantation.

References

1. Tujios S., Stravitz R. T., Lee W. M. Seminars in liver disease. – Thieme Medical Publishers, Inc. **42**. 03. 362-378 (2022)
2. Sarin S. K., Choudhury A. Nature Reviews Gastroenterology & Hepatology **13**. 3. 131-149 (2016)
3. Kumar R, Anand U, Priyadarshi RN. World J. Transplant. **11(6):**187-202 (2021). doi: 10.5500/wjt.v11.i6.187.
4. Ibadov R. A. et al. Surgery. Journal named after NI Pirogov **8**. 61-67 (2018)
5. Matveev A.V. Hepatoprotectors. Analysis of international studies on drugs from the group of drugs for the liver (Simferopol: IT "ARIAL", 2013)
6. Safinia N, Vaikunthanathan T, Lechler RI, Sanchez-Fueyo A, Lombardi G. Eur. J Immunol. **51(10):**2373-2386 (2021). doi: 10.1002/eji.202048875.
7. Sorkine P, Ben Abraham R, Brill S, Szold O. Isr. Med. Assoc. J. **3(1):**44-9 (2001)
8. Ling S, Jiang G, Que Q, Xu S, Chen J, Xu X. Liver Int. **42(9):**2110-2116 (2022). doi: 10.1111/liv.15288.
9. Minina M.G., Voronov D.V., Tenchurina E.A. Russian Journal of Transplantology and Artificial Organs. **24(3):**102-110 (2022). https://doi.org/10.15825/1995-1191-2022-3-102-110
10. Mito M., Kusano M., Kawaura Y. Transplant. Proc. **24**. 6. 3052–3053 (1992)
11. Urazmetova M. D., Khadzhibaev F. A., Mirzakulov A. G. Bulletin of emergency medicine **14**. 5. 107-113 (2021)
12. Iansante V., Mitry R.R., Filippi C. et al. Pediatr. Res. **83**. 1–2. 232–240 (2018). https://doi.org/10.1038/pr.2017.284
13. Nahar S., Nakashima Y., Miyagi-Shiohira C. et al. World J. Stem Cells. **10**. 11. 146–159 (2018). Doi: 10.4252/wjsc.v10.i11.146
14. Gal Perin EI, Ataullakhanov RI, Dyuzheva TG, et al. Biomeditsinskaia Khimiia. **63(5):**440-446 (2017). DOI: 10.18097/pbmc20176305440. PMID: 2908087
15. Irwin M. The liver: biology and pathobiology (New York: Raven Press, 1994)
16. K. Yanagita, M. Nagaike, H. Ishibashi, Y. Niho, K. Matsumoto, T. Nakamura // Biochem. Biophys. Res. Commun. **182**, 2. 802–809 (1992)
17. Zhao Y. et al. Frontiers in Pharmacology. **13** (2022). DOI: 10.3389/fphar.2022.808855
18. Bland M. An introduction to medical statistics. (Oxford university press, 2015)
19. RU No. 2781448 C1, 10/12/2022 Bulletin. No. 29; Application No. 2021124602 dated 08/18/21. Inozemtsev P.O., Lepekhova S.A., Kostyro Ya.A., Makoshina P.S., Goldberg O.A. Pharmaceutical composition for obtaining lyophilisate of liver cell culture, enriched with hepatocyte growth factor.

RETRACTED